secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYCOR MEDICAL INC (VYCO)
CIK:        0001424768
Form:       8-K
Filed at:   2026-08-14T20:13:30+00:00
Accession:  0001493152-26-038366
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vycor Medical Q2 revenue down 16% to $418K; operating profit falls to $6.9K
---------------------------------------------------------------------------

- Q2 2026 revenue $418,264, down 16% YoY; Vycor Medical division down 17% to $401,224 on international weakness.
- Q2 operating profit $6,851 vs $51,146 in 2025; non-GAAP operating profit $22,952 vs $85,712.
- Six-month revenue $876,804, down 6%; operating profit $52,659 vs $38,340 in 2025.
- NovaVision in development: Q2 revenue $17,040, up 17% YoY; six-month $35,139, up 8%.
- Three new peer-reviewed VBAS studies published in 2026; total now 53 peer-reviewed papers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1424768/000149315226038366/0001493152-26-038366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1424768/000149315226038366/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-038366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer